SARS-CoV-2 convalescent plasma / French Defence Health Service Headquarters - LARVOL DELTA

PLASCOSSA: Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients. (clinicaltrials.gov) - P3 | N=18 | Terminated | Sponsor: Direction Centrale du Service de Santé des Armées | New variants have appeared since the plasma collection period. Some recent publications question the effectiveness of transfusion.

Enrollment change • Trial termination • Critical care • Infectious Disease • Novel Coronavirus Disease

PLASCOSSA: Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients. (clinicaltrials.gov) - P3; N=80; Recruiting; Sponsor: Direction Centrale du Service de Santé des Armées; Not yet recruiting ➔ Recruiting; Initiation date: May 2020 ➔ Sep 2020; Trial primary completion date: Oct 2020 ➔ May 2021

Clinical • Enrollment open • Trial initiation date • Trial primary completion date • Critical care • Infectious Disease • Novel Coronavirus Disease

PLASCOSSA: Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients. (clinicaltrials.gov) - P3; N=80; Not yet recruiting; Sponsor: Direction Centrale du Service de Santé des Armées

Clinical • New P3 trial